RU2013121799A - Набор для претаргетинга, способ и агенты, применяемые в нем - Google Patents

Набор для претаргетинга, способ и агенты, применяемые в нем Download PDF

Info

Publication number
RU2013121799A
RU2013121799A RU2013121799/15A RU2013121799A RU2013121799A RU 2013121799 A RU2013121799 A RU 2013121799A RU 2013121799/15 A RU2013121799/15 A RU 2013121799/15A RU 2013121799 A RU2013121799 A RU 2013121799A RU 2013121799 A RU2013121799 A RU 2013121799A
Authority
RU
Russia
Prior art keywords
alkyl
aryl
group
independently
bio
Prior art date
Application number
RU2013121799/15A
Other languages
English (en)
Russian (ru)
Inventor
Йохан ЛУБ
ХУВЕ Волтер ТЕН
Раффаэлла РОССИН
ДЕН БОС Сандра Мартина ВАН
Марк Стефан РОБИЙАР
Original Assignee
Конинклейке Филипс Электроникс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Конинклейке Филипс Электроникс Н.В. filed Critical Конинклейке Филипс Электроникс Н.В.
Publication of RU2013121799A publication Critical patent/RU2013121799A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0495Pretargeting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
RU2013121799/15A 2010-10-14 2011-10-11 Набор для претаргетинга, способ и агенты, применяемые в нем RU2013121799A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10187619 2010-10-14
EP10187619.1 2010-10-14
PCT/IB2011/054481 WO2012049624A1 (en) 2010-10-14 2011-10-11 Pretargeting kit, method and agents used therein

Publications (1)

Publication Number Publication Date
RU2013121799A true RU2013121799A (ru) 2014-11-20

Family

ID=43736149

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013121799/15A RU2013121799A (ru) 2010-10-14 2011-10-11 Набор для претаргетинга, способ и агенты, применяемые в нем

Country Status (5)

Country Link
US (1) US9463256B2 (enExample)
EP (1) EP2627358B1 (enExample)
JP (2) JP6063384B2 (enExample)
RU (1) RU2013121799A (enExample)
WO (1) WO2012049624A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013121799A (ru) * 2010-10-14 2014-11-20 Конинклейке Филипс Электроникс Н.В. Набор для претаргетинга, способ и агенты, применяемые в нем
EP2522369A1 (en) * 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2709666B1 (en) 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
US20150166596A1 (en) * 2012-05-21 2015-06-18 Agilent Technologies, Inc. Retro Diels Alder Reaction as a Cleavable Linker in DNA/RNA Applications
EP2922574B1 (en) 2012-11-22 2023-05-17 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081299A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081301A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014117001A1 (en) * 2013-01-25 2014-07-31 Memorial Sloan-Kettering Cancer Center Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US9366784B2 (en) 2013-05-07 2016-06-14 Corning Incorporated Low-color scratch-resistant articles with a multilayer optical film
US9110230B2 (en) 2013-05-07 2015-08-18 Corning Incorporated Scratch-resistant articles with retained optical properties
WO2014205126A1 (en) 2013-06-19 2014-12-24 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
JP2017501010A (ja) 2014-01-04 2017-01-12 ヴィジャイ アガーワル 光線力学的療法の利用のための装置及び方法
WO2015117235A1 (en) * 2014-02-10 2015-08-13 Mcmaster University Targeted molecular imaging contrast agents
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
ES2871029T3 (es) * 2014-04-04 2021-10-28 Harvard College Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos
US11267973B2 (en) 2014-05-12 2022-03-08 Corning Incorporated Durable anti-reflective articles
US9790593B2 (en) 2014-08-01 2017-10-17 Corning Incorporated Scratch-resistant materials and articles including the same
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
JP2018536177A (ja) 2015-09-14 2018-12-06 コーニング インコーポレイテッド 高光線透過性かつ耐擦傷性反射防止物品
EP3153155B1 (en) * 2015-10-08 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
MA49398A (fr) * 2017-05-05 2020-04-22 Eric Steven Burak Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
US11559494B2 (en) 2017-07-14 2023-01-24 The Penn State Research Foundation Compositions and methods for targeted delivery of therapeutic and/or diagnostic species
GB201720769D0 (en) 2017-12-13 2018-01-24 Univ Of Northumbria At Newcastle Pericyclic reactions
MX2020006395A (es) 2017-12-18 2020-12-03 Janssen Biotech Inc Radioetiquetado de polipeptidos.
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
CA3099421C (en) 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
CN114085038A (zh) 2018-08-17 2022-02-25 康宁股份有限公司 具有薄的耐久性减反射结构的无机氧化物制品
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020167992A1 (en) 2019-02-13 2020-08-20 Craniovation, Inc. Non-invasive sonodynamic therapy
CN114096276A (zh) 2019-05-29 2022-02-25 索纳拉森公司 声敏化
CN114599645A (zh) 2019-06-17 2022-06-07 泰克沃尔科斯制药有限公司 用于在体内从生物分子中裂解标记的试剂
US12386101B2 (en) 2020-07-09 2025-08-12 Corning Incorporated Textured region of a substrate to reduce specular reflectance incorporating surface features with an elliptical perimeter or segments thereof, and method of making the same
US12589162B2 (en) 2020-08-07 2026-03-31 Tambo, Inc. Trans-cyclooctene prodrug of monomethyl auristatin E
CA3185803A1 (en) 2020-08-07 2022-02-10 Vijay Agarwal Ultrasound arrays for enhanced sonodynamic therapy for treating cancer
AU2022262350B2 (en) 2021-04-20 2026-05-07 Terrapower Isotopes, Llc Titania based generators for ac-225 generation
EP4108669A1 (en) * 2021-06-24 2022-12-28 Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. Carbohydrate derivatives and kits for cell surface labeling
JP2025519296A (ja) * 2022-06-13 2025-06-26 フィクレッティン サヒン 抗ウイルス効果のためのルテチウム塩化合物の使用
WO2025059685A1 (en) * 2023-09-15 2025-03-20 Tambo, Inc. Methods for in vivo targeted delivery of a payload

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
EP2026840A2 (en) * 2005-10-04 2009-02-25 Koninklijke Philips Electronics N.V. Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition
WO2010051530A2 (en) * 2008-10-31 2010-05-06 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
BRPI1006246A2 (pt) 2009-04-16 2020-02-04 Koninl Philips Electronics Nv "kit para imagem médica marcada e/ou terapias, sonda efetora e método"
RU2013121799A (ru) * 2010-10-14 2014-11-20 Конинклейке Филипс Электроникс Н.В. Набор для претаргетинга, способ и агенты, применяемые в нем
EP2922574B1 (en) * 2012-11-22 2023-05-17 Tagworks Pharmaceuticals B.V. Chemically cleavable group

Also Published As

Publication number Publication date
CN103269721A (zh) 2013-08-28
WO2012049624A1 (en) 2012-04-19
EP2627358B1 (en) 2024-03-27
US20130189184A1 (en) 2013-07-25
JP2014506869A (ja) 2014-03-20
JP6063384B2 (ja) 2017-01-18
JP6368745B2 (ja) 2018-08-01
US9463256B2 (en) 2016-10-11
JP2016193934A (ja) 2016-11-17
EP2627358C0 (en) 2024-03-27
EP2627358A1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
JP2016193934A5 (enExample)
JP2014518861A5 (enExample)
RU2013133813A (ru) Средства для выведения биомолекул из кровотока
RU2011146322A (ru) Набор для предварительного придания направленности действия, способ и средства, применяемые в нем
KR101931382B1 (ko) 토륨 방사성 핵종 및 히드록시피리디논 함유 리간드를 포함하는 표적화된 알파-입자 방출 복합체
EP2357166B1 (en) Auto magnetic metal salen complex compound
PT92619B (pt) Processo para a preparacao de complexos do acido aminofosfonico e de formulacoes com base no referido acido
JP5781007B2 (ja) ホスホルアミデートアルキル化剤プロドラッグ
JP5421114B2 (ja) 低酸素症選択性の弱塩基性2−ニトロイミダゾール送達薬剤およびその使用方法
CA3171183A1 (en) Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto
US20050238578A1 (en) High dose radionuclide complexes for bone marrow suppression
NO20051108L (no) Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse
RU2011107752A (ru) Агенты, связывающиеся с psma, и их применение
KR20080039508A (ko) 인데노이소퀴놀리논 유사체 및 이의 사용 방법
AR068897A1 (es) Inhibidores de proteasoma
WO2008043911A3 (fr) Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant
JP2016504325A (ja) 放射線と組み合わせて使用するための放射線増感剤化合物
US20040067924A1 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
WO2001085736A1 (en) Porphyrin-based neutron capture agents for cancer therapy
Vincent et al. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy
ES2743276T3 (es) Derivados de ácido hidroxibisfosfónico bifuncionales
AU2017283653C1 (en) Porphyrin compounds and compositions useful for treating cancer
RU2014132184A (ru) Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
El-Mabhouh et al. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer